Work with MEK1/2 inhibitors such as selumetinib is encouraging and effective in the majority of NF1 participants with PNs or low-grade gliomas, and the drug was recently granted FDA approval for the treatment of NF1 PN (Dombi et al., 2016; Gross et al., 2018, 2020). This evidence concerns the gene NF1 and glioma.